穆克吉也将他自己的病人的故事写进了这部历史，虽然这些故事并不总是一帆风顺。
Mukherjee stitches stories of his own patients into this history, not always smoothly.
结论：吉西他滨联合顺铂的新辅助化疗耐受性好，并且没有破坏胰腺癌的可手术性。
Conclusion: Neoadjuvant chemotherapy with gemcitabine and cisplatin is well tolerated and does not impair resectability of pancreatic cancer.
同时，这些患者既往不能有包含吉西他滨或者顺铂的化疗史。
Patients could not have had prior chemotherapy with gemcitabine or cisplatin.
目的评价长春瑞滨（NVB）与顺铂（DDP）及吉西他滨（GEM）与顺铂联合化疗治疗晚期非小细胞癌（NSCLC）的疗效及毒副作用。
Objective To evaluate the toxicity and clinical activity of navelbine(NVB) plus cisplation(DDP) and gemcitabine(GEM) plus cisplation in the treatment of advanced non-small cell lung cancer(NSCLC).
替吉奥联合顺铂作为一种新的新辅助化疗方案，治疗胃癌总缓解率达76％，是目前为止进展期胃癌化疗方案中缓解率最高的方案。
S-1 combined with CDDP as a new neoadjuvant chemotherapy, is the most efficient therapy in advanced gastric cancer at present, it's CR can be over 76%.
替吉奥联合顺铂作为一种新的新辅助化疗方案，治疗胃癌总缓解率达76％，是目前为止进展期胃癌化疗方案中缓解率最高的方案。
S-1 combined with CDDP as a new neoadjuvant chemotherapy, is the most efficient therapy in advanced gastric cancer at present, it's CR can be over 76%.
应用推荐